Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.7, 2013-07, pp. : 893-899

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

By Sharma Anant Shah Sachin R. Illum Henrik Dowell Jonathan

Drugs, Vol. 72, Iss. 17, 2012-12 ,pp. : 2207-2222

Adis International

Access to resources Recommend Favorite

Dabrafenib for the treatment of melanoma

By Amaria Rodabe N Kim Kevin B

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 1043-1050

Informa Healthcare

Access to resources Recommend Favorite

Emerging BRAF inhibitors for melanoma

By Sabbatino Francesco Wang Yangyang Wang Xinhui Ferrone Soldano Ferrone Cristina R

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 4, 2013-12 ,pp. : 431-443

Informa Healthcare

Access to resources Recommend Favorite

BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects

Current Cancer Drug Targets, Vol. 14, Iss. 2, 2014-02 ,pp. : 128-143

Bentham Science Publishers

Access to resources Recommend Favorite

Drugs in Clinical Development for Melanoma†: Summary and Table

Pharmaceutical Medicine, Vol. 26, Iss. 3, 2012-06 ,pp. : 171-183

Adis International

Access to resources Recommend Favorite